You are viewing an incomplete version of our website. Please click to reload the website as full version.

anti-Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Antibodies

PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Additionally we are shipping PCSK9 Kits (72) and PCSK9 Proteins (61) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
PCSK9 255738 Q8NBP7
PCSK9 100102 Q80W65
PCSK9 298296 P59996
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-PCSK9 Antibodies at antibodies-online.com

Showing 10 out of 154 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Goat Un-conjugated IHC (p), WB 0.1 mg Log in to see 6 to 8 Days
$379.50
Details
Human Goat Un-conjugated EIA, WB HEK293 lysate (10 µg protein in RIPA buffer) overexpressing Human PCSK9 with C-terminal MYC tag probed with AP22408PU-N (1 µg/ml) in Lane A and probed with anti-MYC Tag (1/1000) in lane C. Mock-transfected HEK293 probed with AP22408PU-N (1mg/ml) in Lane B. Primary incubations were for 1 hour. Detected by chemiluminescence. 0.1 mg Log in to see 6 to 8 Days
$390.50
Details
Human Rabbit Un-conjugated EIA, WB Western blot analysis of PCSK9 Antibody (N-term) in Jurkat cell line lysates (35ug/lane). PCSK9 (arrow) was detected using the purified Pab. 0.4 mL Log in to see 6 to 8 Days
$390.50
Details
Human Rabbit Un-conjugated FACS, IHC (p), WB Western blot analysis of PCSK9 Antibody (N-term) (ABIN652320) in Jurkat cell line lysates (35 µg/lane). PCSK9 (arrow) was detected using the purified polyclonal antibody. PCSK9 Antibody (N-term) (ABIN652320) IHC analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining 400 μL Log in to see 10 to 11 Days
$324.50
Details
Human Rabbit Un-conjugated FACS, IHC (p), WB Western blot analysis of PCSK9 antibody (C-term) (ABIN391505) in Hela cell line lysates (35 µg/lane). PCSK9 (arrow) was detected using the purified polyclonal antibody. PCSK9 Antibody (C-term) (ABIN391505) IHC analysis in formalin fixed and paraffin embedded human Colon carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining 400 μL Log in to see 10 to 11 Days
$324.50
Details
Human Goat Un-conjugated EIA, WB HEK293 lysate (10 µg protein in RIPA buffer) overexpressing Human PCSK9 with C-terminal MYC tag probed with AP22407PU-N (0.5 µg/ml) in Lane A and probed with anti-MYC Tag (1/1000) in lane C. Mock-transfected HEK293 probed with AP22407PU-N(1mg/ml) in Lane B. Primary incubations were for 1 hour. Detected by chemiluminescence. 0.1 mg Log in to see 6 to 8 Days
$390.50
Details
Human Goat Un-conjugated IHC, ELISA, WB ABIN185371 staining (0.2 µg/mL) of McA cell lysates: untransfected (1), transfected with wild type human pcsk9 (2), transfected with S127R human pcsk9 (3). Data kindly provided by Dr. X-M Sun, Hammersmith Hospital, London. ABIN185371 (0.3 µg/mL) staining of Human Adipose lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 100 μg Log in to see 6 to 7 Days
$326.89
Details
Human Goat Un-conjugated ChIP, IHC (p), IHC, ELISA, WB Western Blot: PCSK9 Antibody [ABIN268772] - Analysis of PCSK9 in McA cell lysates: untransfected (1), transfected with wild type human PCSK9 (2), transfected with S127R human PCSK9 (3) using ABIN268772 (0.2ug/ml). Data kindly provided by Dr. X-M Sun, Hammersmith Hospital, London. Western Blot: PCSK9 Antibody [ABIN268772] - (0.3ug/ml) staining of Human Adipose lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 0.1 mg Log in to see 7 to 9 Days
$447.56
Details
Human Rabbit Un-conjugated IHC (p), WB Anti-PCSK9 antibody, IHC(P) IHC(P): Human Intestinal Cancer Tissue 100 μg Log in to see 4 to 6 Days
$200.00
Details
Human Rabbit Un-conjugated IF (p), IHC (p), WB Formalin-fixed and paraffin embedded mouse brain labeled with Rabbit Anti-NARC1 Polyclonal Antibody, Unconjugated (ABIN761831) at 1:200 followed by conjugation to the secondary antibody and DAB staining 100 μL Log in to see 3 to 7 Days
$307.45
Details

PCSK9 Antibodies by Reactivity, Application, Clonality and Conjugate

Attributes Applications Host Clonality Conjugate
Human , ,
, , ,
,
, , , , , , , , , , , , , , , ,
Mouse (Murine) , , , ,
, ,
,
, , , , , , , , , , , , ,
Rat (Rattus) , , , ,
, ,
,
, , , , , , , , , , , , ,

Top referenced anti-PCSK9 Antibodies

  1. Human Polyclonal PCSK9 Primary Antibody for ChIP, IHC (p) - ABIN268772 : Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005 (PubMed)
    Show all 10 references for ABIN268772

  2. Human Polyclonal PCSK9 Primary Antibody for IHC (p), WB - ABIN374535 : Lambert, Ancellin, Charlton, Comas, Pilot, Keech, Patel, Sullivan, Cohn, Rye, Barter: Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. in Clinical chemistry 2008 (PubMed)
    Show all 3 references for ABIN374535

  3. Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN453778 : McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. in The Journal of biological chemistry 2009 (PubMed)
    Show all 3 references for ABIN453778

  4. Human Polyclonal PCSK9 Primary Antibody for IHC, ELISA - ABIN185371 : Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005 (PubMed)
    Show all 2 references for ABIN185371

  5. Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN652320 : Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. in Journal of human genetics 2004 (PubMed)
    Show all 2 references for ABIN652320

  6. Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN391505 : Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... in Nature genetics 2003 (PubMed)
    Show all 2 references for ABIN391505

  7. Human Polyclonal PCSK9 Primary Antibody for IF (p), IHC (p) - ABIN761831 : Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016 (PubMed)

  8. Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN569616 : Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008 (PubMed)

More Antibodies against PCSK9 Interaction Partners

Human Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) interaction partners

  1. Low LDL cholesterol levels due to PCSK9 and HMGCR (show HMGCR Antibodies) variants had no causal effect on high risk of Alzheimer's disease, vascular dementia, any dementia, or Parkinson's disease; however, low LDL cholesterol levels may have a causal effect in reducing the risk of Alzheimer's disease.

  2. conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (show CA2 Antibodies)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (show LDLR Antibodies) degradation and promoting LDLR (show LDLR Antibodies)-dependent hepatic cholesterol uptake.

  3. Even though LDLR (show LDLR Antibodies)-R410S and LDLR (show LDLR Antibodies)-WT were similar in levels of cell surface and total receptor and bound equally well to LDL or extracellular PCSK9, the LDLR (show LDLR Antibodies)-R410S was resistant to exogenous PCSK9-mediated degradation in endosomes/lysosomes and showed reduced LDL internalization and degradation relative to LDLR (show LDLR Antibodies)-WT.

  4. Lipid therapy today and tomorrow: anti-PCSK9

  5. First human antibodies were recently approved as the first immunotherapeutic agents for the treatment of severe hypercholesterolemia and in patients with statin intolerance. An additional PCSK9 antibody is presently being studied in phase III clinical trials.[review]

  6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein (LDL) receptors leading to their degradation in the liver. Inhibition of PCSK9 leads to an increase in LDL receptors and as a result to a reduction of LDL cholesterol in blood. [review]

  7. Furthermore, the effect of reduction of LDL-C by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and by the cholesteryl ester transfer protein (CETP (show CETP Antibodies)) inhibitor anacetrapib on cardiovascular events is currently being investigated in large clinical outcome study programs. [review]

  8. Further information on long-term efficacy, tolerability and cost-effectiveness of PCSK9 inhibition and possibilities of implementation in the healthcare system are awaited from ongoing clinical outcome trials, such as FOURIER, ODYSSEY OUTCOMES, SPIRE 1 (show SPIRE1 Antibodies) and 2 involving more than 70,000 high-risk patients. [review]

  9. The 2 or 4week subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60 %. [review]

  10. study provides the first evidence that GPC3 (show GPC3 Antibodies) can modulate the PCSK9 extracellular activity as a competitive binding partner to the LDLR (show LDLR Antibodies) in HepG2 cells.

Mouse (Murine) Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) interaction partners

  1. conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (show CA2 Antibodies)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (show LDLR Antibodies) degradation and promoting LDLR (show LDLR Antibodies)-dependent hepatic cholesterol uptake.

  2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (show LDLR Antibodies) Degradation.

  3. PCSK9 increases hepatic lipid and lipoprotein production via apoE (show APOE Antibodies)- and LDLR (show LDLR Antibodies)-dependent mechanisms

  4. Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.

  5. polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.

  6. binding of PCSK9 to GRP94 (show HSP90B1 Antibodies) protects LDLR (show LDLR Antibodies) from degradation likely by preventing early binding of PCSK9 to LDLR (show LDLR Antibodies)

  7. The absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR (show LDLR Antibodies) and VLDLR (show VLDLR Antibodies), which is determined by estradiol levels.

  8. that ox-LDL receptor-1 (show OLR1 Antibodies) and PCSK9 positively influence each other's expression, especially during an inflammatory reaction

  9. Data show that leptin (show LEP Antibodies) treatment suppresses proprotein convertase subtilisin/kexin type 9 (PCSK9) in male, but fails to suppress PCSK9 in female.

  10. The Liver Clock Controls Cholesterol Homeostasis through Trib1 (show TRIB1 Antibodies) Protein-mediated Regulation of PCSK9/Low Density Lipoprotein Receptor (LDLR (show LDLR Antibodies)) Axis.

PCSK9 Antigen Profile

Protein Summary

This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).

Gene names and symbols associated with PCSK9

  • proprotein convertase subtilisin/kexin type 9 (pcsk9) antibody
  • proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody
  • proprotein convertase subtilisin/kexin type 9 (Pcsk9) antibody
  • proprotein convertase subtilisin/kexin type 9-like (LOC100620501) antibody
  • AI415265 antibody
  • AI747682 antibody
  • FH3 antibody
  • HCHOLA3 antibody
  • LDLCQ1 antibody
  • NARC-1 antibody
  • Narc1 antibody
  • PC9 antibody

Protein level used designations for PCSK9

proprotein convertase subtilisin/kexin type 9 , convertase subtilisin/kexin type 9 preproprotein , neural apoptosis regulated convertase 1 , subtilisin/kexin-like protease PC9 , NARC-1 , convertase subtilisin , neural apoptosis-regulated convertase 1 , proprotein convertase 9 , proprotein convertase PC9 , proprotein convertase subtilisin/kexin type 9 preproprotein , Proprotein convertase 9 , Subtilisin/kexin-like protease PC9

GENE ID SPECIES
495509 Xenopus laevis
100150316 Danio rerio
100544916 Meleagris gallopavo
255738 Homo sapiens
100102 Mus musculus
298296 Rattus norvegicus
424664 Gallus gallus
100731533 Cavia porcellus
717147 Macaca mulatta
100971792 Pan paniscus
456880 Pan troglodytes
100395116 Callithrix jacchus
100620501 Sus scrofa
Selected quality suppliers for anti-PCSK9 (PCSK9) Antibodies
Did you look for something else?